AUTHORS
Breanna Chandler, M.D., Ronay Thomas, MD2, Joseph Giannini, MSN, ANP-BC3, Angela Kerins, PharmD4, Nathan Mitchell, PharmD5, Kenneth S. Cohen Jr, MD6, Valerie G Press, MD7, Nabil Abou Baker, MD8
AFFILIATIONS
1 University of Chicago, Chicago, Illinois, United States
2 University of Chicago, Chicago, Illinois, United States
3 University of Chicago, Chicago, Illinois, United States
4 University of Chicago, Chicago, Illinois, United States
5 University of Chicago, Chicago, Illinois, United States
6 University of Chicago, Chicago, Illinois, United States
7 University of Chicago, Chicago, Illinois, United States
8 University of Chicago, Chicago, Illinois, United States
ABSTRACT
Introduction:
Sickle cell disease (SCD) is associated with vaso-occlusive pain episodes that frequently require emergency department (ED) evaluation and subsequent hospitalization for treatment. Buprenorphine (BUP) has emerged as an alternative analgesic strategy for chronic pain management in adults with SCD, but its impact on healthcare utilization has not been well defined. We evaluated changes in ED visits and hospitalizations before and after BUP initiation in adults with SCD.
Methods:
We performed a retrospective electronic medical record review of adults with SCD who received BUP therapy for at least three months and did not have a prior diagnosis of opioid use disorder (OUD) at the University of Chicago Medical Center. De-identified ED-only visits (EDO) and ED visits with subsequent hospitalization or direct admissions (EDH) data were evaluated during three time periods: the calendar year preceding BUP initiation, the calendar year of BUP initiation, and the subsequent calendar year after initiation. Follow-up data were available through July 24, 2026. Demographic variables and opioid utilization were assessed through the EMR.
Patients with acute-on-chronic pain were offered BUP if they were admitted for at least 7 days on IV opioids and unable to wean despite offering Ketamine or Lidocaine, or if they had at least 2 admissions in the last 30 days. Patients were also offered BUP in the outpatient setting if they had chronic pain that required a long-acting opioid.
For patients whose post-treatment period occurred in 2026, EDO and EDH were annualized to events per patient-year to account for incomplete follow-up. The primary analysis included 22 patients. Because data were non-normally distributed and included large numbers of multi-visit observations, paired Wilcoxon signed-rank tests were used to compare utilization across study periods. Paired t-tests were performed as secondary analyses. A sensitivity analysis, excluding the two multi-visit patients, was conducted to evaluate the influence of outliers. Pearson correlation and simple linear regression were used to assess the relationship between post-BUP EDO and EDH. The study was conducted as a quality improvement initiative and was not overseen by an Institutional Review Board.
Results:
Twenty-two patients met inclusion criteria. In the primary analysis, EDO did not differ significantly between the pre-BUP and initiation years (median of 2.5 and 3, respectively, p = 0.875), the initiation and post-BUP years (median of 3 and 1.9, respectively, p = 0.117), or the pre- and post-BUP years (median of 2.5 and 1.9, respectively, p = 0.127). EDH were not significantly different between the pre-BUP and initiation years (median of 6.5 and 7.5, respectively, p = 0.513) but were significantly lower during the post-BUP period compared with both the initiation year (median of 3.3 and 6.5, respectively, p = 0.006) and the pre-BUP year (median of 3.3 and 7.5, respectively, p = 0.025).
Sensitivity analysis excluding the two highest multi-visit patients (n = 20) demonstrated a significant reduction in EDO between the initiation and post-BUP years (median of 3 and 1.8, respectively, p = 0.007), while the comparison between the pre- and post-BUP periods approached statistical significance (median of 2.5 and 1.8, respectively, p = 0.059). Reductions in EDH remained significant after excluding these patients for both the initiation versus post-BUP comparison (median of 7.5 and 3.3, respectively, p = 0.001) and the pre- versus post-BUP comparison (median of 7 and 3.3, respectively, p = 0.005).
Conclusion:
Among adults with SCD treated with BUP, EDH was significantly lower during the post-treatment period, whereas EDO remained unchanged in the primary analysis. Sensitivity analyses demonstrated that the EDH findings were robust after exclusion of two high-visit patients, while ED visits were more strongly influenced by these observations. These findings suggest that BUP therapy may be associated with reduced healthcare utilization in adults with SCD.
Interpretation of these results, however, are limited by the retrospective single-center design, small sample size, incomplete follow-up requiring annualization of 2026 data, and the potential influence of unmeasured confounding factors. Larger prospective, multicenter studies are needed to further evaluate these findings.
This study continues to support the use of buprenorphine in chronic pain management for patients with SCD.
DISCLOSURES
Breanna Chandler, M.D.: No relevant conflicts of interest to declare.